PRME at a glance
Prime Medicine, Inc. (PRME, SEC CIK 1894562) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as June 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Prime Medicine, Inc. (PRME) reported revenue of $4.6 million (up 55.3% from FY2024) and a net loss of $201.1 million. Diluted EPS was -$1.35.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Prime Medicine, Inc. (PRME) shares worth $182.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $4.6M
- +55.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $182.5M · +0 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Risk factors remain updated through the June 30, 2026 Form 10-Q
Management Discussion & Analysis
- Quarterly revenue: not disclosed; no product sales, collaboration revenue only
- R&D expenses $34.1M vs $44.0M YoY, down $9.9M
- G&A expenses $10.0M vs $11.2M YoY, down $1.2M
- Cash, equivalents and investments $61.2M at September 30, 2026, including restricted cash $74.8M
- Operating cash outflow $120.4M for nine months, with $109.2M investment maturities; November offering added $134.7M net proceeds
AI summary of the PRME 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Prime Medicine’s Q3 2026 results and business highlights cover the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for the financial figures, operating performance and updated business developments
Item EX-99.1: Item EX-99.1
- First patient dosed in PM577a Phase 1/2 Wilson disease trial, marking Prime Medicine’s first in vivo clinical program
- FDA cleared PM647’s IND for Alpha-1 Antitrypsin Deficiency, with initial clinical data from PM577a and PM647 expected in 2027
Item 1.01: Entry into a Material Definitive Agreement
- $125.0 million base equity offering: 35,714,286 shares priced at $3.50 each
- Additional 5,357,142-share underwriter option, potentially increasing gross proceeds
Item 2.02: Results of Operations and Financial Condition
- Preliminary liquidity of $61.2 million in cash, equivalents and short-term investments as of September 30, 2026
- Restricted cash adds approximately $13.7 million, but is unavailable for general operating use
Item 8.01: Other Events
- Updated corporate presentation posted November 10, 2026, providing investors with the company’s latest strategy and program materials
- Exhibit 99.1 contains the substantive presentation, requiring review for pipeline, clinical, financial, and corporate updates
Item EX-99.1: Item EX-99.1
- Prime Medicine targets Phase 1/2 initial data for PM577a Wilson disease and PM647 AATD programs in 2027
- PM359 CGD program advancing toward BLA submission in the first half of 2027, pending final FDA alignment
AI summaries of PRME 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PRME
Don't miss the next PRME filing
- Alerts as it files. A push when PRME files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PRME, by share count.
- Ask anything. An AI agent that reads every PRME filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Schenkein David P | A | Jun 5, 2026 | 75,000 | - |
| Chung Wendy | A | Jun 5, 2026 | 75,000 | - |
| Cahill Thomas | A | Jun 5, 2026 | 75,000 | - |
| NELSEN ROBERT | A | Jun 5, 2026 | 75,000 | - |
| Foster-Cheek Kaye I | A | Jun 5, 2026 | 75,000 | - |
| Kelly Michael Aaron | A | Jun 5, 2026 | 75,000 | - |
| Marrazzo Jeffrey D | A | Jun 5, 2026 | 75,000 | - |
| Makhni Svetlana Ni | A | Apr 16, 2026 | 800,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $3.0M | $4.6M |
| Operating Income | - | -$202.5M | -$208.3M |
| Net Income | -$198.1M | -$195.9M | -$201.1M |
| Op. Margin | - | -6787.4% | -4498.1% |
| Net Margin | - | -6566.6% | -4342.4% |
| Balance Sheet | |||
| Total Assets | $193.9M | $297.5M | $342.7M |
| Equity | - | $153.1M | $120.9M |
| ROE | - | -127.9% | -166.4% |
| Per Share | |||
| EPS | $-2.18 | $-1.65 | $-1.35 |
| Cash Flow | |||
| Operating CF | - | -$122.9M | -$162.6M |
| CapEx | $8.7M | $7.3M | $4.5M |
Source: XBRL data in Prime Medicine, Inc. (PRME)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PRME share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $182.5M |
| Q2 2026 | 28 | $230.5M |
| Q1 2026 | 28 | $189.5M |
| Q4 2025 | 26 | $190.9M |
| Q3 2025 | 25 | $259.6M |
| Q2 2025 | 23 | $84.4M |
| Q1 2025 | 20 | $61.9M |
| Q4 2024 | 17 | $95.5M |
- ARK Investment Management+1.69M (+20%)
- BlackRock+1.11M (+12%)
- Millennium Management+632.5K (+148%)
- Bank of America Corp+236.7K (+24%)
- Vanguard Capital Management LLC+56.9K (+1%)
- Citadel Advisors LLC−1.59M (-78%)
- State Street Corp−1.43M (-19%)
- Goldman Sachs Group−594.3K (-17%)
- D.E. Shaw & Co−332.8K (-51%)
- Dimensional Fund Advisors−291.3K (-96%)
- Allstate+37.0K
- Principal Financial Group+10.3K
- U.S. Bancorp+230
- FMR LLC (Fidelity)−1.76M
- Renaissance Technologies LLC−117.4K
- PNC Financial Services−319
Source: 13F-HR filings on SEC EDGAR (aggregated from 195 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PRME filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 8, 2026 | - | Analysis | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 17, 2026 | - | - | - |
| 8-K | Apr 16, 2026 | - | Analysis | - |
| 10-K | Mar 3, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 3, 2026 | - | Analysis | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 8-K | Jan 12, 2026 | - | - | |
| SC 13G | Nov 14, 2025 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
PRME SEC filings: frequently asked questions
Which institutions hold PRME stock?
As of September 30, 2026, the largest Prime Medicine, Inc. (PRME) holders among the 13F filers tracked by SignalX were Alphabet Inc ($50.7 million), BlackRock ($32.7 million), ARK Investment Management ($30.7 million), State Street Corp ($18.8 million), Vanguard Capital Management LLC ($14.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PRME's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Prime Medicine, Inc. (PRME) reported revenue of $4.6 million (up 55.3% from FY2024) and a net loss of $201.1 million. Diluted EPS was -$1.35. The figures come from the XBRL data in the 10-K.
What did PRME report in its latest 8-K?
Prime Medicine, Inc. (PRME) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Prime Medicine’s Q3 2026 results and business highlights cover the quarter ended September 30, 2026.
What are the latest PRME SEC filings?
Prime Medicine, Inc. (PRME) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on June 8, 2026.
What is PRME's SEC CIK number?
Prime Medicine, Inc. (PRME)'s SEC Central Index Key (CIK) is 1894562. EDGAR lists every PRME filing under that number.
Ask anything about PRME
The research agent reads PRME's filings, financials, insider trades and 13F holders, then answers with sources.